A Novel nanoemulsion for Optimised Wound recovery-NOW:a topical antibiotic-free approach

仅在英国，每年约有200万患者遭受急性或慢性伤口，导致发病率增加和医疗保健系统的高经济负担，估计约为53亿英镑。病理性伤口愈合和瘢痕形成是主要的医学问题，尽管伤口护理管理取得了进步，但目前的皮肤恢复方法通常不能提供令人满意的临床结果，通常面临诸如皮肤恢复效率低、瘢痕组织形成过多和可能的感染等挑战，特别是在慢性伤口治疗中。尽管已经开发了许多具有抗生素的局部制剂，但由于抗菌素耐药性的上升率（估计到2050年每年导致1000万人死亡）以及缺乏用于刺激肉芽组织产生和抑制瘢痕组织形成的微量营养素，它们的功效受到损害。该项目旨在通过技能和知识转移来探索这些挑战，为无菌伤口皮肤恢复的新方法产生和测试想法，直接为英国政府对抗抗菌素耐药性的愿景做出贡献。该项目将通过从萨里大学借调一名早期职业研究人员到一家生物技术中小企业- Phytoceutical来实现。主办机构，生物技术中小企业Phytoceutical已经开发和测试了用于术前和术后皮肤护理的微营养素包封技术，包括视黄醇（维生素A的最生物利用形式）。该公司的视黄醇局部纳米乳液是稳定的，并已被证明可以穿透皮肤的物理屏障，而没有全身毒性作用。该项目探索了将公司的知识产权用于皮肤修复的新方法，将天然化合物和具有经验证的抗菌性能的替代防腐剂用于对抗与抗生素使用相关的抗菌素耐药性。借调通过提供获得一系列技能和知识的机会，促进了借调人员的职业发展，包括小型灵活的公司如何竞争并为市场带来新的创新，获得资金支持，与希望获得产品的最终用户和早期市场采用者合作，并在产品商业化之前了解监管环境。该项目还促进了Phytoceutical Ltd和萨里大学研究团队之间的长期合作，使公司和学术机构之间的知识，想法和专业知识互补交流。此外，该项目允许为大学探索新的研究途径，包括伤口护理先进模型和抗生素耐药性解决方案，并为合作伙伴之间未来的合作资金建立知识和技能基础，以推动伤口恢复。

In the UK alone, around 2 million patients suffer acute or chronic wounds every year, causing increased morbidity and high economic burden to the healthcare system estimated around £5.3 billion. Pathological wound healing and scar formation are major medical problems and despite advancements in wound care management, current skin recovery approaches generally fail to provide a satisfactory clinical outcome, commonly facing challenges such as inefficient skin recovery, excess scar tissue formation and possible infections, particularly with chronic wound treatment. Although numerous topical formulations with antibiotics have been developed, their efficacy is compromised due to the rising rates of antimicrobial resistance that is estimated to cause 10 million deaths every year by 2050 and the lack of micronutrients for stimulating granulation tissue production and inhibiting scar tissue formation. This project aims to explore these challenges by skills and knowledge transfer, generating and testing ideas for novel approaches for antibiotic-free wound skin recovery, directly contributing to UK government's vision for combating antimicrobial resistance. This project will be realised through the secondment of an early career researcher from the University of Surrey to a biotechnology SME- Phytoceutical.The hosting organisation, biotechnology SME Phytoceutical has developed and tested technology for encapsulating micronutrients including retinol (the most bioavailable form of vitamin A) for pre-and post- operative skin care. The company's retinol topical nanoemulsion is stable and has been proven to penetrate the physical skin barrier without systemic toxicity effects. This project explores new ways for adapting the company's IP for skin recovery, incorporating natural compounds and alternative antiseptics with proven antimicrobial properties for combating antimicrobial resistance related to antibiotics use.The secondment boosts the secondee's career development, by opening the opportunity for a range of skills and knowledge to be gained, including how small, agile companies can compete and bring new innovations to the market, access funding support, work with end-users and early market adopters who desire the products and navigate the regulatory environment prior to product commercialisation. The project also promotes a long-term collaboration between Phytoceutical Ltd and the University of Surrey's research team that enables complementary exchange of knowledge, ideas and expertise between the company and the academic institution. Furthermore, the project allows new research avenues to be explored for the University including in wound care advanced models and antibiotic resistance solutions and builds the knowledge and skills foundation for future collaborative funding between the partners to take wound recovery forward.